Locations
Seattle, WA, USA · University of Washington, Seattle, WA, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series C+
founded in
2011
Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for rare respiratory diseases, particularly pulmonary fibrosis and other interstitial lung diseases. Their lead candidate, AP01, is currently in a Phase 2b study and is an inhaled formulation of pirfenidone aimed at treating pulmonary fibrosis. The company differentiates itself by utilizing inhaled formulations of approved medications, targeting conditions that significantly affect patient quality of life. With a strong pipeline and a commitment to addressing unmet medical needs, Avalyn Pharma is positioned to make a substantial impact in the biopharmaceutical landscape.
Something looks off?On-site & Remote